Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics

Armitage, E. G. and Southam, A. D. (2016) Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics. Metabolomics, 12(9), 146. (doi:10.1007/s11306-016-1093-7)

[img]
Preview
Text
122990.pdf - Published Version
Available under License Creative Commons Attribution.

822kB

Abstract

Introduction: Cellular metabolism is altered during cancer initiation and progression, which allows cancer cells to increase anabolic synthesis, avoid apoptosis and adapt to low nutrient and oxygen availability. The metabolic nature of cancer enables patient cancer status to be monitored by metabolomics and lipidomics. Additionally, monitoring metabolic status of patients or biological models can be used to greater understand the action of anticancer therapeutics. Objectives: Discuss how metabolomics and lipidomics can be used to (i) identify metabolic biomarkers of cancer and (ii) understand the mechanism-of-action of anticancer therapies. Discuss considerations that can maximize the clinical value of metabolic cancer biomarkers including case–control, prognostic and longitudinal study designs. Methods: A literature search of the current relevant primary research was performed. Results: Metabolomics and lipidomics can identify metabolic signatures that associate with cancer diagnosis, prognosis and disease progression. Discriminatory metabolites were most commonly linked to lipid or energy metabolism. Case–control studies outnumbered prognostic and longitudinal approaches. Prognostic studies were able to correlate metabolic features with future cancer risk, whereas longitudinal studies were most effective for studying cancer progression. Metabolomics and lipidomics can help to understand the mechanism-of-action of anticancer therapeutics and mechanisms of drug resistance. Conclusion: Metabolomics and lipidomics can be used to identify biomarkers associated with cancer and to better understand anticancer therapies.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Armitage, Dr Emily Grace
Authors: Armitage, E. G., and Southam, A. D.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Metabolomics
Publisher:Springer Verlag
ISSN:1573-3882
ISSN (Online):1573-3890
Published Online:16 August 2016
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in Metabolomics 12:146
Publisher Policy:Reproduced under a creative commons license

University Staff: Request a correction | Enlighten Editors: Update this record